<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321552</url>
  </required_header>
  <id_info>
    <org_study_id>EU PMS Revision 4</org_study_id>
    <nct_id>NCT03321552</nct_id>
  </id_info>
  <brief_title>PROMISE International</brief_title>
  <official_title>Percutaneous Deep Vein Arterialization Post-Market Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LimFlow SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LimFlow SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this post-market study is to evaluate the safety and effectiveness of the&#xD;
      LimFlow System in creating a below-the-knee arterio-venous fistula for venous arterialization&#xD;
      in subjects with critical limb ischemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the safety and effectiveness of the LimFlow System for creating&#xD;
      an arterio-venous fistula in the below-the-knee vascular system using an endovascular,&#xD;
      minimally invasive approach for the treatment of critical limb ischemia in subjects&#xD;
      ineligible for conventional endovascular or surgical limb salvage procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amputation-free survival</measure>
    <time_frame>Throughout one year</time_frame>
    <description>Freedom from death or major amputation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound healing</measure>
    <time_frame>Throughout one year</time_frame>
    <description>Complete index wound healing as assessed by wound pictures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary and secondary patency as assessed by duplex ultrasound</measure>
    <time_frame>Throughout one year</time_frame>
    <description>Stent graft patency as assessed by duplex ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb salvage: Freedom from major amputation</measure>
    <time_frame>Throughout one year</time_frame>
    <description>Freedom from major amputation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deterioration in renal function as assessed by creatinine level</measure>
    <time_frame>One month and six months</time_frame>
    <description>Changes in creatinine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success (procedure completion)</measure>
    <time_frame>Immediately post-procedure</time_frame>
    <description>Procedure completion and immediate morphological success with successful placement of the arterial and venous catheters in the desired location in the limb, and ability to place the stent graft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success (technical success without death, major amputation, or re-intervention)</measure>
    <time_frame>One month post-procedure</time_frame>
    <description>Combination of technical success without death, major amputation, or re-intervention</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Percutaneous deep vein arterialization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous deep vein arterialization</intervention_name>
    <description>Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach</description>
    <arm_group_label>Percutaneous deep vein arterialization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LimFlow System</intervention_name>
    <description>Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach</description>
    <arm_group_label>Percutaneous deep vein arterialization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be &gt; 21 and &lt; 95 years of age&#xD;
&#xD;
          -  Clinical diagnosis of symptomatic critical limb ischemia, defined as Rutherford&#xD;
             category 5 or 6&#xD;
&#xD;
          -  Assessment that no conventional surgical or endovascular treatment is possible&#xD;
&#xD;
          -  Proximally, the target in-flow artery at the cross-over point must be treatable with a&#xD;
             3.5 - 4.0 mm stent after pre-treatment (by visual estimate), and be &lt;50% stenosed&#xD;
&#xD;
          -  Subject is willing and has adequate support to comply with protocol requirements,&#xD;
             including medication regimen and follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant hepatic insufficiency, deep venous thrombus in target limb, uncorrected&#xD;
             coagulation disorders, or current immunodeficiency disorder&#xD;
&#xD;
          -  Prior vein stripping surgery and/or vessel harvesting for CABG in the limb intended&#xD;
             for study&#xD;
&#xD;
          -  Life expectancy less than 12 months&#xD;
&#xD;
          -  Patient currently taking coumarin/warfarin which, in the opinion of the attending&#xD;
             physician, interferes with the patient's treatment&#xD;
&#xD;
          -  Any significant medical condition which, in the attending physician's opinion, may&#xD;
             interfere with the patient's optimal treatment&#xD;
&#xD;
          -  Patient currently participating in another investigational drug or device study that&#xD;
             has not completed the primary endpoint or that clinically interferes with the&#xD;
             endpoints of this treatment&#xD;
&#xD;
          -  Patient unable to give consent&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Documented myocardial infarction or stroke within previous 90 days&#xD;
&#xD;
          -  Patients suffering from renal insufficiency (GFR value less than 30 ml/min/1.73 m²)&#xD;
             who are not on hemodialysis&#xD;
&#xD;
          -  Patients with vasculitis and/or untreated popliteal aneurysms&#xD;
&#xD;
          -  Patients with acute limb ischemia&#xD;
&#xD;
          -  Prior peripheral arterial bypass procedure above or below the knee which could inhibit&#xD;
             proximal inflow to the stent graft&#xD;
&#xD;
          -  Lower extremity venous disease with significant edema in the target limb that may&#xD;
             inhibit the procedure and/or jeopardize wound healing, in the investigator's opinion&#xD;
&#xD;
          -  Known or suspected systemic or severe infection (e.g., WIfI foot Infection grade of 3)&#xD;
&#xD;
          -  Known or suspected allergies or contraindications to stainless steel, nickel, or&#xD;
             contrast agent that cannot be adequately pre-treated, or patients who cannot receive&#xD;
             anticoagulation or antiplatelet aggregation therapy&#xD;
&#xD;
          -  Severe heart failure, which in the opinion of the investigator may compromise&#xD;
             subject's ability to safely undergo a percutaneous procedure (e.g., known ejection&#xD;
             fraction of &lt; 40%, NYHA Classification III-IV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vincent Cabane, MSc</last_name>
    <phone>+33603861713</phone>
    <email>vcabane@limflow.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dittmar Böckler, MD</last_name>
      <phone>+49 6221 56 - 34193</phone>
      <email>Dittmar.Boeckler@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SRH Klinikum Karlsbad-Langensteinbach</name>
      <address>
        <city>Karlsbad</city>
        <state>Baden-Württemberg</state>
        <zip>76307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwin Blessing, MD</last_name>
      <phone>+49 (0) 7202 61-3471</phone>
      <email>Erwin.Blessing@srh.de</email>
    </contact>
    <contact_backup>
      <last_name>Bernd Kroeg</last_name>
      <phone>+49 (0) 7202 61-3471</phone>
      <email>Bernd.Kroeg@srh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Erwin Blessing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Arnsberg GmbH</name>
      <address>
        <city>Arnsberg</city>
        <state>North Rhine-Westphalia</state>
        <zip>59755</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lichtenberg, MD</last_name>
      <phone>+49-(0)2932-9521271</phone>
      <email>M.Lichtenberg@klinikum-arnsberg.de</email>
    </contact>
    <investigator>
      <last_name>Michael Lichtenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Franziskus-Hospital GmbH</name>
      <address>
        <city>Münster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arne Schwindt, MD</last_name>
      <phone>0251/9352321</phone>
      <email>Arne.Schwindt@SFH-MUENSTER.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrej Schmidt, MD</last_name>
      <phone>+49-341-97 18774</phone>
      <email>Andrej.Schmidt@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5200 ME</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Willem Hinnen, MD</last_name>
      <phone>+31 (073) 553 20 00</phone>
      <email>j.hinnen@jbz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Noordwest Ziekenhuisgroep</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michiel Schreve, MD</last_name>
      <phone>+310251265555</phone>
      <email>mschreve@rkz.nl</email>
    </contact>
    <investigator>
      <last_name>Michiel Schreve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel van den Heuvel, MD</last_name>
      <phone>+31646216968</phone>
      <email>d.van.den.heuvel@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Daniel van den Heuvel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pua Uei, MD</last_name>
      <phone>+65 6357 8394</phone>
      <email>pua_uei@ttsh.com.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tan Yih Kai, MD</last_name>
      <phone>+65 6850 2600</phone>
      <email>yih_kai_tan@cgh.com.sg</email>
    </contact>
    <contact_backup>
      <last_name>Steven Kum, MD</last_name>
      <phone>+65 6850 2600</phone>
      <email>steven_kum@cgh.com.sg</email>
    </contact_backup>
    <investigator>
      <last_name>Tan Yih Kai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Schreve MA, Lichtenberg M, Ünlü Ç, Branzan D, Schmidt A, van den Heuvel DAF, Blessing E, Brodmann M, Cabane V, Lin WTQ, Kum S. PROMISE international; a clinical post marketing trial investigating the percutaneous deep vein arterialization (LimFlow) in the treatment of no-option chronic limb ischemia patient. CVIR Endovasc. 2019 Jul 31;2(1):26. doi: 10.1186/s42155-019-0067-z.</citation>
    <PMID>32026120</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Desert foot</keyword>
  <keyword>No-option patients</keyword>
  <keyword>Venous arterialization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

